|
|
 |
| MACS® GMP Recombinant Human IL-6 |
|
| Description |
Interleukin 6 (IL-6) is a cytokine showing growth-inducing, growth-inhibitory, and differentiation-inducing effects in a cell type–specific manner. IL-6 acts as both a pro-inflammatory and anti-inflammatory cytokine. It is mainly produced by monocytes and macrophages, but as well by epithelial or endothelial cells. IL-6 is one of the most important mediators of fever and of the acute phase response affecting B lymphocytes, T lymphocytes, and hybridoma cells. In combination with other factors like human interleukin 2 and interferon γ it also affects cytotoxic T lymphocytes. MACS GMP Recombinant Human IL-6 is lyophilized without carrier protein or preservatives. A lot-specific certificate confirms identity, molecular mass, specific activity, sterility, purity, endotoxin content, and host-cell DNA content. |
| Applications |
MACS GMP Recombinant Human IL-6 can be used for a variety of applications, including the ex vivo generation of human dendritic cells from enriched CD14+ monocytes.1-3 MACS GMP Recombinant Human IL-6 is not intended for human in vivo application. |
| Quality Statement |
MACS GMP Recombinant Human IL-6 may be used for research or ex vivo cell culture processing. MACS GMP Recombinant Human IL-6 is manufactured and tested under a certified ISO 9001 quality system and in compliance with relevant GMP guidelines. It is designed following the recommendations of USP <1043> on ancillary materials. No animal- or human-derived components are used for manufacturing. |
| | |
|
 |
| My favorites |
| Your current favorite list is empty. |
|
| Products |
| MACS GMP Recombinant Human IL-6 |
| For research or ex vivo cell culture processing |
| Availability: Worldwide (1) |
Components - 10 μg Download datasheet 170-076-104
|
| (1) For availability in your country please contact your local representative. |
|
| References |
| 1. Bender et al. (1996) J. Immunol. Methods 196: 121–135. |
| 2. Romani et al. (1996) J. Immunol. Methods 196: 137–151. |
| 3. Jonuleit et al. (1997) Eur. J. Immunol. 27: 3135–3142. |
|
|
|
© 1999 - 2010 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|